TCM
CPRX

Teza Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Teza Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,831
Closed -$263K – 351
2025
Q1 		$263K Sell
10,831
-10,086
-48% -$227K 0.12% 294
2024
Q4 		$437K Buy
+20,917
New +$449K 0.07% 305
2024
Q2 		– Sell
-11,871
Closed -$189K – 608
2024
Q1 		$189K Buy
+11,871
New +$179K 0.03% 524

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Teza Capital Management's CPRX Position: Q2 2025 in Review

Teza Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 10,831 shares — an estimated $263K sold.

Teza Capital Management first reported a position in CPRX in Q1 2024 and held it in 3 quarters. The position peaked at $437K in Q4 2024. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

  • Teza Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Teza Capital Management sold 10,831 Catalyst Pharmaceutical shares in Q2 2025, an estimated $263K.
  • Teza Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 3 quarters.
  • Teza Capital Management's Catalyst Pharmaceutical position peaked at $437K in Q4 2024.
  • 365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on Teza Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.